Advertisement

Document › Details
Evotec SE. (2/4/22). "Press Release: Bayer Discontinues Clinical Development Candidate Eliapixant (BAY1817080), Evotec Regains the Rights to All P2X3 Assets [Ad hoc release]". Hamburg.
![]() |
Organisation | Evotec SE (FSE: EVT, MDA X/TecDAX, Nasdaq: EVO) |
Group | Evotec (Group) | |
Organisation 2 | Bayer AG | |
Group | Bayer (Group) | |
![]() |
Product | eliapixant (BAY 1817080) |
Product 2 | drug development | |
![]() |
Person | Lanthaler, Werner (Evotec AG 200903– CEO before Intercell AG CFO before Austrian Industrial Assoc before McKinsey) |
Evotec SE (Frankfurt Stock Exchange, MDAX/TecDAX, ISIN: DE 000 566480 9, WKN 566480; NASDAQ) announces today that the Company has been informed by Bayer about a decision to discontinue the development of the investigational P2X3 receptor antagonist eliapixant (BAY1817080), which stems from a former Evotec/Bayer multi-target research alliance.
Following a review of the available data, Bayer concluded that the overall benefit no longer outweighs the risk in the actively pursued indications.
As a consequence of Bayer's decision, Evotec regains the rights to all P2X3 assets. The Company will evaluate the underlying data as soon as they are made available and will evaluate all options.
This decision has no impact on the overall strategic goals as outlined in Action Plan 2025.
- End of ad hoc release -
Contact: Dr Werner Lanthaler, Chief Executive Officer, Evotec SE, Manfred Eigen Campus, Essener Bogen 7, 22419 Hamburg, Germany, Phone: +49.(0)40.560 81-242, werner.lanthaler@evotec.com
Record changed: 2022-02-17 |
Advertisement
![Picture [iito] Männer Ballett 650x100px](/banner/iito-business-intelligence-20211013-650-100-summer-banner-series-maenner-ballett.jpg)
More documents for Evotec (Group)
- [1] Ascenion GmbH. (6/21/22). "Press Release: Carma Fund I Completes First Closing of EUR 47 Million to Accelerate the Transfer of Life-Science Research into Practice". Munich & Frankfurt a. M.....
- [2] Evotec SE. (6/14/22). "Press Release: Evotec Enters a Drug Discovery Collaboration with Janssen". Hamburg....
- [3] Evotec SE. (5/30/22). "Press Release: Evotec Adds Cell Therapy Manufacturing Facility with Acquisition of Rigenerand". Hamburg....
- [4] Evotec SE. (5/19/22). "Press Release: Evotec and Almirall Enter into a Multi-target Alliance in Medical Dermatology". Hamburg & Barcelona....
- [5] Evotec SE. (5/17/22). "Press Release: Evotec and Sernova Announce Exclusive Strategic Partnership for iPSC-based Beta Cell Replacement Therapy to Advance a 'Functional Cure' for Diabetes". Hamburg & London, ON....
- [6] Evotec SE. (5/10/22). "Press Release: Evotec and Bristol Myers Squibb Extend and Expand Strategic Partnership in Protein Degradation". Hamburg....
- [7] Evotec SE. (3/21/22). "Press Release: Evotec Receives €3m Milestone Payment for Bayer Starting Phase II Clinical Development of DNP Programme". Hamburg....
- [8] IMIdomics, Inc.. (2/15/22). "Press Release: IMIDomics, Inc. Announces Strategic Investment from Drug Discovery and Research Leader Evotec SE". San Rafael, CA & Barcelona....
- [9] Bayer AG. (2/4/22). "Press Release: Bayer Will Discontinue Phase II Development Candidate eliapixant [only for specialized press]". Berlin....
- [10] Evotec SE. (1/25/22). "Press Release: Evotec Enters iPSC-based Drug Discovery Partnership with Boehringer Ingelheim in Ophthalmology". Hamburg....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement

» top